These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Proceedings of the Workshop on Antimetabolites and the Central Nervous System (New York, NY, February 2-3, 1976): Introduction: antimetabolites and central nervous system neoplasia. Shapiro WR; Mehta BM; Hutchison DJ Cancer Treat Rep; 1977 Jul; 61(4):505-8. PubMed ID: 328143 [No Abstract] [Full Text] [Related]
27. Esters of chlorohydroxyacetone in chemotherapy of murine tumors. Babiarz-Tracy P; McCarthy D; Simon P; Burlingham WJ; Fondy TP Cancer Res; 1980 Sep; 40(9):3274-80. PubMed ID: 7427941 [No Abstract] [Full Text] [Related]
28. Nitrogen mustard: the origin of chemotherapy for cancer. Einhorn J Int J Radiat Oncol Biol Phys; 1985 Jul; 11(7):1375-8. PubMed ID: 3891698 [No Abstract] [Full Text] [Related]
29. [Chemotherapy in adenocarcinomas of the pancreas]. Huguier M Gastroenterol Clin Biol; 2002 Nov; 26(11):1063; discussion 1063-4. PubMed ID: 12483149 [No Abstract] [Full Text] [Related]
30. ICRF-187 in clinical oncology. Poster DS; Penta JS; Bruno S; Macdonald JS Cancer Clin Trials; 1981; 4(2):143-6. PubMed ID: 6788388 [TBL] [Abstract][Full Text] [Related]
31. Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. Wilke H; Korn M; Vanhöfer U; Fink U; Stahl M; Preusser P; Köhne C; Klassen U; Harstrick A; Schmoll HJ; Seeber S J Infus Chemother; 1996; 6(3):123-6. PubMed ID: 9229322 [TBL] [Abstract][Full Text] [Related]
32. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Clark JW Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-19-S18-24. PubMed ID: 9420017 [TBL] [Abstract][Full Text] [Related]
33. [Drug therapy for inoperable gastric cancer: current possibilities and perspectives of development]. Volkov NM; Moiseenko VM Vopr Onkol; 2007; 53(4):383-92. PubMed ID: 17969398 [No Abstract] [Full Text] [Related]
34. [The antineoplastic effect of violamycins and lambdamycin in experimental leukemias]. Gutsche W; Jungstand W; Wohlrabe K Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):647-51. PubMed ID: 6172328 [No Abstract] [Full Text] [Related]
35. Planning combined therapy--the interaction of experimental and clinical studies. Carter SK Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498 [No Abstract] [Full Text] [Related]
36. Biochemical aspects of drug combinations. Brockman RW Cancer Chemother Rep 2; 1974 Mar; 4(1):115-29. PubMed ID: 4135108 [No Abstract] [Full Text] [Related]
37. Review of the application of response surface methodology in the combination therapy of cancer. Carter WH; Wampler GL Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113 [No Abstract] [Full Text] [Related]
38. Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Chua YJ; Zalcberg JR Expert Rev Anticancer Ther; 2008 Apr; 8(4):595-604. PubMed ID: 18402526 [TBL] [Abstract][Full Text] [Related]
39. [The development of cancer chemotherapy in the USSR]. Larionov LF Vopr Onkol; 1967; 13(8):3-34. PubMed ID: 4879275 [No Abstract] [Full Text] [Related]
40. Kethoxal bis(thiosemicarbazone). I. Effects against experimental tumors. Mihich E; Nichol CA Cancer Res; 1965 Oct; 25(9):1410-6. PubMed ID: 5217028 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]